<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04000763</url>
  </required_header>
  <id_info>
    <org_study_id>STUDY19010062</org_study_id>
    <nct_id>NCT04000763</nct_id>
  </id_info>
  <brief_title>Superficial Peroneal Nerve Neuromodulation for Non-Obstructive Urinary Retention</brief_title>
  <official_title>Superficial Peroneal Nerve Neuromodulation for Non-Obstructive Urinary Retention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katherine Shapiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Society of Urodynamics, Female Pelvic Medicine &amp; Urogenital Reconstruction</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Millions of Americans are suffering from underactive bladder (UAB). The impact of severe UAB,
      i.e. non-obstructive urinary retention (NOUR) on quality of life is significant because
      current treatment for non-obstructive urinary retention requires intermittent
      self-catheterization or an indwelling suprapubic catheter. Currently an effective drug for
      non-obstructive urinary retention does not exist. It is a therapeutic challenge for
      clinicians to successfully treat non-obstructive urinary retention. Sacral neuromodulation
      has been approved by the FDA since 1999 to treat non-obstructive urinary retention. It
      achieves &gt;50% improvement in bladder emptying (reducing the frequency of self-catheterization
      or increasing voided volume) in just over half of the patients. Sacral neuromodulation
      requires surgical implantation of a stimulator and a lead with 4 electrodes. The surgery and
      implant are invasive and expensive, preventing a broad application of this effective therapy
      to many non-obstructive urinary retention patients. The goal of this study is to develop a
      novel non-invasive neuromodulation therapy for non-obstructive urinary retention as an
      alternative. Specifically, the investigators will explore the possibility to translate into
      humans a recent discovery in cats of an excitatory reflex from the superficial peroneal nerve
      to the bladder to treat non-obstructive urinary retention. Therefore, in this study the
      investigators propose to develop a non-invasive, transcutaneous neuromodulation therapy for
      non-obstructive urinary retention that can be administered at home.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: Electrical stimulation of the superficial peroneal nerve using transcutaneous
      skin electrodes attached on the dorsal foot can treat non-obstructive urinary retention
      either by enhancing bladder sensation thereby reducing bladder volume needed for initiating
      voiding and/or by enhancing bladder contraction, thereby increasing voiding efficiency and
      reducing post-void residual (PVR) volume.

      Rationale: The investigators conducted preliminary studies in cats that have demonstrated an
      excitatory reflex to the bladder elicited by stimulation of afferent axons in the superficial
      peroneal nerve. Activating this excitatory reflex in cats reduced bladder capacity (the
      minimal volume for initiating a micturition reflex), enhanced bladder contractions and
      overcame bladder inhibition emanating from somatic (tibial) afferent activation. Since the
      superficial peroneal nerve innervates the dorsal skin of the foot in humans, it can be
      stimulated non-invasively by skin surface electrodes. Transcutaneous stimulation of this
      nerve, should it prove efficacious, would likely be more acceptable to patients with
      non-obstructive urinary retention (NOUR) than invasive sacral neuromodulation therapy.
      Therefore, in this study, the investigators propose to test the superficial peroneal nerve
      neuromodulation in non-obstructive urinary retention patients.

      Specific Aim: Determine the efficacy of superficial peroneal nerve stimulation (SPNS) in the
      treatment of patients with non-obstructive urinary retention using skin electrodes attached
      to the dorsal surface of the foot.

      Rationale: Based on a preliminary discovery in cats, the investigators propose to further
      investigate the effect of superficial peroneal nerve stimulation (SPNS) on voiding
      efficiency, post-void residual (PVR) volume, and bladder capacity (voided volume + post-void
      residual) in patients with non-obstructive urinary retention. A reduced bladder capacity
      indicates more normal bladder filling sensations, thereby allowing voiding at more normal
      volumes. The investigators plan to test superficial peroneal nerve stimulation in 20
      non-obstructive urinary retention patients by collecting voiding diary during a 3-week
      period. Baseline voiding diary will be collected during the first week before superficial
      peroneal nerve stimulation initiation. During the second week, superficial peroneal nerve
      stimulation will be administered to each patient for 3 hours/day before sleep and it will
      also be administered immediately prior and throughout each void. The 3-hour stimulation is
      designed to modulate bladder sensory pathways to enhance bladder sensation, thereby reducing
      the bladder volume required to initiate voiding. The acute stimulation during each void is
      designed to enhance bladder contraction, thereby increasing voiding efficiency and reducing
      post-void residual. During the third week, superficial peroneal nerve stimulation will not be
      applied, and a voiding diary will be collected to determine any post-stimulation effect.
      Since the superficial peroneal nerve is a cutaneous nerve innervating the skin of the dorsal
      foot, superficial peroneal nerve stimulation will be applied non-invasively by attaching skin
      surface electrodes to the dorsal side of the foot.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 20, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All experiments proposed in this grant application will be performed in female non-obstructive urinary retention patients. We chose not to study male patients in this study given the need to exclude bladder outlet obstruction from benign prostatic hyperplasia (BPH), an evaluation that is invasive and costly.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of voids per subject in 24 hours.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Counted using a patient voiding diary both before and after superficial peroneal nerve stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of catheterizations per subject in 24 hours.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Counted using a patient voiding diary both before and after superficial peroneal nerve stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of urine per void.</measure>
    <time_frame>3 weeks</time_frame>
    <description>Calculated in millimeters both before and after peroneal nerve stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Catheterized Post Void Residual volume</measure>
    <time_frame>3 weeks</time_frame>
    <description>Calculated in millimeters both before and after peroneal nerve stimulation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bladder Voiding efficiency</measure>
    <time_frame>3 weeks</time_frame>
    <description>Pre voiding and post voiding ratio that reflects bladder contractility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bladder capacity</measure>
    <time_frame>3 weeks</time_frame>
    <description>Calculated by adding the voided volume to the post residual catheterization volume, in milliliters</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Foot Stimulation</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in millimeters of bladder emptying capacity from week 2 to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of Foot Stimulation</measure>
    <time_frame>3 weeks</time_frame>
    <description>Difference in millimeters of bladder emptying capacity from week 3 to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-stimulation effect</measure>
    <time_frame>1 week</time_frame>
    <description>Difference in millimeters of bladder emptying capacity from week 2 to week 3.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Urinary Retention</condition>
  <condition>Urinary Bladder, Underactive</condition>
  <arm_group>
    <arm_group_label>Transcutaneous Nerve Stimulator(TENS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult females who have difficulty emptying their bladder due to non-obstructive urinary retention or because of an under-active bladder will be given transcutaneous nerve stimulation (TENS) therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>superficial peroneal nerve stimulation</intervention_name>
    <description>A commercially available FDA-approved transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes will be used to stimulate the foot. The electrodes will be attached to the dorsal surface of the foot and a sock will be placed over the foot to prevent detachment of the electrodes. Based on our animal studies, foot stimulation parameters of 2 Hz frequency and 0.2 ms pulse width will be used at the maximal intensity comfortable for each patient. It is expected that superficial peroneal nerve stimulation in patients can increase bladder sensation so that micturition can be initiated at a small bladder volume, or it can initiate bladder contraction at a small bladder volume and enhance the contraction or prolong the duration of contraction. Any of these excitatory effects, if occurs in human patients, will certainly improve the condition of non-obstructive urinary retention.</description>
    <arm_group_label>Transcutaneous Nerve Stimulator(TENS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Able to provide informed consent

          1. 18 years of age and older

          2. Clinically diagnoses as non-obstructive urinary retention

          3. Post Void Residual of 300 mL or greater

          4. Currently using daily self-catheterization to empty the bladder

          5. Capable of using the toilet independently without difficulty

          6. Capable and willing to follow all study-related procedures

        Exclusion Criteria:

          1. Neurologic diagnosis (including diabetes mellitus)

          2. Surgery within one year of screening for urinary outlet obstruction

          3. Pregnant or planning to become pregnant during study duration

          4. OnabotulinumtoxiA use in bladder or pelvic floor muscles with the past year

          5. Pacemaker or implantable defibrillator

          6. Current Urinary tract or vaginal infections

          7. Current Interstim use

          8. Current Percutaneous tibial nerve stimulation (PTNS) or transcutaneous electrical
             nerve stimulation (TENS) use in pelvis or back or legs

          9. Investigational drug/ device therapy with the past 4 weeks,

         10. Participation in any clinical investigation involving or impacting gynecologic or
             urinary function with the past 4 weeks,

         11. Previous surgery of or damage to the foot or nerves in the foot and leg.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Shapiro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christopher Chermansky, MD</last_name>
    <role>Study Director</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Okonski, BS</last_name>
    <phone>412-692-4099</phone>
    <email>ericksonjr@upmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>UPMC Urology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet Okonski, BS</last_name>
      <phone>412-692-4099</phone>
      <email>ericksonjr@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Christopher Chermansky, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Shapiro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Janet Okonski, BS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>26872574</citation>
  </reference>
  <reference>
    <citation>Juszczak K, Drewa T. Pharmacotherapy in detrusor underactivity: A new challenge for urologists and pharmacologists (from lab to clinic). Pharmacol Rep. 2016 Aug;68(4):703-6. doi: 10.1016/j.pharep.2016.03.007. Epub 2016 Mar 19. Review.</citation>
    <PMID>27110877</PMID>
  </reference>
  <reference>
    <citation>Kessler TM, Fowler CJ. Sacral neuromodulation for urinary retention. Nat Clin Pract Urol. 2008 Dec;5(12):657-66. doi: 10.1038/ncpuro1251. Epub 2008 Nov 11. Review.</citation>
    <PMID>19002127</PMID>
  </reference>
  <reference>
    <citation>De Ridder D, Ost D, Bruyninckx F. The presence of Fowler's syndrome predicts successful long-term outcome of sacral nerve stimulation in women with urinary retention. Eur Urol. 2007 Jan;51(1):229-33; discussion 233-4. Epub 2006 Jul 10.</citation>
    <PMID>16860462</PMID>
  </reference>
  <reference>
    <citation>Faraj K, Doo F, Boura J, Vereecke A, Chancellor MB. A cross-sectional study in the USA of the epidemiology and quality of life of underactive bladder symptoms. Int Urol Nephrol. 2016 Nov;48(11):1797-1802. Epub 2016 Jul 29.</citation>
    <PMID>27473156</PMID>
  </reference>
  <reference>
    <citation>Abarbanel J, Marcus EL. Impaired detrusor contractility in community-dwelling elderly presenting with lower urinary tract symptoms. Urology. 2007 Mar;69(3):436-40.</citation>
    <PMID>17382138</PMID>
  </reference>
  <reference>
    <citation>Goodwin RJ, Swinn MJ, Fowler CJ. The neurophysiology of urinary retention in young women and its treatment by neuromodulation. World J Urol. 1998;16(5):305-7.</citation>
    <PMID>9833308</PMID>
  </reference>
  <reference>
    <citation>Yu M, Uy J, Jiang X, Li X, Jones C, Shen B, Wang J, Roppolo JR, de Groat WC, Tai C. An excitatory reflex from the superficial peroneal nerve to the bladder in cats. Am J Physiol Renal Physiol. 2017 Nov 1;313(5):F1161-F1168. doi: 10.1152/ajprenal.00265.2017. Epub 2017 Aug 30.</citation>
    <PMID>28855188</PMID>
  </reference>
  <reference>
    <citation>Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats. Am J Physiol Renal Physiol. 2011 Feb;300(2):F385-92. doi: 10.1152/ajprenal.00526.2010. Epub 2010 Nov 24.</citation>
    <PMID>21106856</PMID>
  </reference>
  <results_reference>
    <citation>Jonas U, Fowler CJ, Chancellor MB, Elhilali MM, Fall M, Gajewski JB, Gr√ºnewald V, Hassouna MM, Hombergh U, Janknegt R, van Kerrebroeck PE, Lylcklama a Nijeholt AA, Siegel SW, Schmidt RA. Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol. 2001 Jan;165(1):15-9.</citation>
    <PMID>11125353</PMID>
  </results_reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 23, 2019</study_first_submitted>
  <study_first_submitted_qc>June 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 27, 2019</study_first_posted>
  <last_update_submitted>January 22, 2020</last_update_submitted>
  <last_update_submitted_qc>January 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Katherine Shapiro</investigator_full_name>
    <investigator_title>Graduate Medical Resident</investigator_title>
  </responsible_party>
  <keyword>Bladder</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Retention</mesh_term>
    <mesh_term>Urinary Bladder, Underactive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data and methods will be shared with other investigators upon signed data use agreements and assurance of Institutional Review Board approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After all data is collected and analyzed.</ipd_time_frame>
    <ipd_access_criteria>Data Use Agreement Institutional Review Board approval.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

